TRIPS Council to discuss IP and the public interest in the context of Covid-19
The search for new treatments and vaccines needed to respond to the Covid-19 outbreak has laid bare some key issues around intellectual property (IP)...
The European Commission’s proposal on a new EU-wide compulsory licensing regime
Guest author Olga Gurgula is a Senior Lecturer in Intellectual Property Law at Brunel Law School, Brunel University London
A recent international health emergency, the...
New Dutch Foundation to Address High Medicines Pricing Announces Plan to File Complaint with...
The newly established Dutch Pharmaceutical Accountability Foundation has announced its first action to address unreasonably high medicines prices in the Netherlands. The Foundation will...
Medicines Law & Policy responds to US Health and Human Services Department request for...
On 12 December 2023 the US Health and Human Services Department (HHS) posted a notice and request for comments on “the implications of access...
WHO’s Essential Medicines Committee takes aim at rising prices, adds new treatments for cancer...
On 1 October, the World Health Organization published its latest Model List of Essential Medicines (EML) and Essential Medicines for Children (EMLc). Updated roughly...
Humiragate: AbbVie’s desperate attempts to keep its monopoly
A new front has opened in the war against Abbvie's efforts to sustain and secure its Humira market monopoly. This time in The Netherlands...
Drug Price Transparency Calls Move from South Africa to World Health Assembly
by Katrina Perehudoff and Jennifer Sellin
Over 30 states and 40 business and civil society groups debated strategies for affordable and sustainable medicines prices at...
Something is going terribly wrong with the EU Compulsory Licensing Regulation
This week the European Parliament will vote on amendments to the Commission’s proposed regulation of the European Parliament and the Council on compulsory licensing...
Why The Request By Least Developed Countries For An Extension Of The Transitional Period...
On 24 February 2015 Bangladesh on behalf of the 34 Least Developed Country members (LDCs) of the World Trade Organization (WTO) submitted a request...
Pharmaceutical Accountability Foundation is taking AbbVie to court over excessive pricing of Humira –...
On 21 February, the Dutch Pharmaceutical Accountability Foundation (PAF) took the bold step to take AbbVie to court, claiming the company’s pricing policy had...